A new mouse model mimicking the liver symptoms of myotonic dystrophy type 1 -- the most prevalent form of adult-onset muscular dystrophy -- provides insight into why patients develop fatty liver ...

"Myotonic Dystrophy Type 1 is an aggressive and challenging neuromuscular disorder affecting not only adults, but also children and has no approved treatment option for any age group," said Judith ...

A new mouse model mimicking the liver symptoms of myotonic dystrophy type 1—the most prevalent form of adult-onset muscular dystrophy—provides insight into why patients develop fatty liver ...

ARTHEx Biotech S.L., a clinical-stage biotechnology company focused on developing innovative medicines through the modulation of gene expression, today announced that the U.S. Food and Drug ...

US FDA grants rare paediatric designation to ARTHEx Biotech’s ATX-01 for the treatment of myotonic dystrophy type 1: Valencia, Spain Friday, November 8, 2024, 16:00 Hrs [IST] AR ...

Analyst Michael Ulz from Morgan Stanley reiterated a Buy rating on Dyne Therapeutics (DYN – Research Report) and keeping the price target ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

The mum of a child with complex needs says she can't thank a local painter enough for the upgrade he's facilitated for her ...

Dyne Therapeutics, Inc. (NASDAQ:DYN – Get Free Report) has been given a consensus rating of “Buy” by the ten ratings firms ...